|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 35.23 USD | -1.62% |
|
-4.86% | -23.91% |
| 05-16 | Collegium Pharmaceutical, Inc. Announces Appointment of Michael Donovan as Director | CI |
| 05-12 | Collegium completes acquisition of Azstarys® from Corium Therapeutics | RE |
Company Valuation: Collegium Pharmaceutical, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 650 | 778.9 | 1,004 | 924 | 1,464 | 1,143 | - | - |
| Change | - | 19.82% | 28.87% | -7.95% | 58.4% | -21.93% | - | - |
| Enterprise Value (EV) 1 | 650 | 778.9 | 1,004 | 924 | 1,464 | 1,893 | 1,470 | 1,143 |
| Change | - | 19.82% | 28.87% | -7.95% | 58.4% | 29.37% | -22.35% | -22.29% |
| P/E | 10x | -31.4x | 23.9x | 15.4x | 26.8x | 13.2x | 9.45x | - |
| PBR | - | - | - | - | - | 3.23x | 2.28x | - |
| PEG | - | 0x | -0x | 0.3x | -3.83x | 0.2x | 0.2x | - |
| Capitalization / Revenue | 2.35x | 1.68x | 1.77x | 1.46x | 1.88x | 1.31x | 1.29x | 1.37x |
| EV / Revenue | 2.35x | 1.68x | 1.77x | 1.46x | 1.88x | 2.17x | 1.66x | 1.37x |
| EV / EBITDA | 5.49x | 2.93x | 2.74x | 2.3x | 3.18x | 3.91x | 3.2x | 2.71x |
| EV / EBIT | 36.9x | 23.4x | 6.01x | 5.44x | 8.15x | 3.99x | 3.38x | 2.93x |
| EV / FCF | - | - | 3.66x | 4.54x | 4.47x | 6.02x | 3.49x | - |
| FCF Yield | - | - | 27.3% | 22% | 22.4% | 16.6% | 28.6% | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 1.86 | -0.74 | 1.29 | 1.86 | 1.73 | 2.66 | 3.73 | - |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 276.9 | 463.9 | 566.8 | 631.4 | 780.6 | 874.6 | 885.9 | 833.9 |
| EBITDA 1 | 118.3 | 266 | 367 | 401.2 | 460.5 | 484.1 | 460.1 | 422.1 |
| EBIT 1 | 17.63 | 33.32 | 167 | 169.9 | 179.6 | 474.5 | 434.5 | 389.7 |
| Net income 1 | 71.52 | -25 | 48.16 | 69.19 | 62.87 | 108.2 | 158.3 | - |
| Net Debt 1 | - | - | - | - | - | 750.9 | 327.7 | - |
| Reference price 2 | 18.68 | 23.20 | 30.78 | 28.65 | 46.30 | 35.23 | 35.23 | 35.23 |
| Nbr of stocks (in thousands) | 34,797 | 33,572 | 32,611 | 32,250 | 31,611 | 32,434 | - | - |
| Announcement Date | 24/02/22 | 23/02/23 | 22/02/24 | 27/02/25 | 26/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 13.46x | 2.19x | 3.95x | - | 1.16B | |
| 35.49x | 12.92x | 26.31x | 0.56% | 1,085B | |
| 27.65x | 6.35x | 17.24x | 2.06% | 624B | |
| 30.17x | 7.39x | 15.12x | 2.74% | 442B | |
| 17.88x | 4.44x | 10.99x | 2.98% | 332B | |
| 21.53x | 5.52x | 13.36x | 2.86% | 282B | |
| 22.38x | 4.7x | 13.12x | 1.86% | 277B | |
| 14.08x | 5.27x | 10.83x | 3.55% | 217B | |
| 23.79x | 6.31x | 11.13x | 2.77% | 196B | |
| -47.8x | 5.8x | 32.25x | 2.41% | 167B | |
| Average | 15.86x | 6.09x | 15.43x | 2.42% | 362.31B | |
| Weighted average by Cap. | 24.02x | 7.98x | 18.48x | 1.97% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- COLL Stock
- Valuation Collegium Pharmaceutical, Inc.
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
